You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Positive results for Lynparza plus abiraterone in metastatic prostate cancer

AstraZeneca and MSD have announced positive results for their PARP inhibitor Lynparza (olaparib) in combination with abiraterone as a first-line treatment for metastatic castration-resistant prostate cancer (mCRPC) patients, with or without homologous recombination repair (HRR) gene mutations.